Chromium
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Chromium: From Trace Element to Osteoarthritis
One-Sentence Summary
Chromium (DB11136) is an essential trace mineral with no formally approved drug indication, historically studied as a nutritional supplement involved in insulin signaling and glucose metabolism. The TxGNN model assigns its highest prediction score to Osteoarthritis (98.68%); however, all retrieved clinical evidence relates to chromium as a component of orthopedic implant alloys — not as a therapeutic drug — making this prediction likely a knowledge graph artifact rather than a genuine therapeutic signal. There are no therapeutic clinical trials and no literature directly supporting chromium supplementation for osteoarthritis.
Analyst Note: The most actionable finding in this Evidence Pack is Rheumatoid Arthritis (rank 3, 98.54%), which has a completed Phase 2/3 RCT (NCT05545020) and pre-clinical mechanistic data for trivalent chromium (Cr³⁺) as an anti-inflammatory agent. A separate “Proceed with Guardrails” evaluation for RA is recommended.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No approved drug indication (essential trace element) |
| Predicted New Indication | Osteoarthritis |
| TxGNN Prediction Score | 98.68% |
| Evidence Level | L4 |
| Canada Market Status | Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for Chromium as a pharmacological agent is currently unavailable. Based on established biochemistry, trivalent chromium (Cr³⁺) — the biologically active, nutritionally essential form — enhances insulin receptor sensitivity by potentiating tyrosine kinase activity, thereby improving cellular glucose uptake. It has also been proposed to suppress NF-κB–mediated inflammatory signaling, reduce circulating pro-inflammatory cytokines (TNF-α, IL-6), and modulate immune cell activity. These properties are broadly relevant to joint diseases where systemic low-grade inflammation plays a pathogenic role.
However, the specific high TxGNN score for osteoarthritis (rank 1) is almost certainly driven by an indirect knowledge graph association rather than a direct therapeutic relationship. The most plausible pathway is: OA → orthopedic joint replacement surgery → cobalt-chromium (CoCr) implant alloys → chromium ion release. This makes chromium appear connected to OA in the graph, but in that context chromium is a byproduct of implant wear — a monitored exposure concern — not a treatment. All 48 clinical trials retrieved for this query involve CoCr alloy implants used in total hip or knee arthroplasty, and none test chromium as a therapeutic intervention.
The situation is meaningfully different for Rheumatoid Arthritis (rank 3), where direct therapeutic evidence does exist: a completed Phase 2/3 RCT (NCT05545020; published as PMID 39030450) compared trivalent chromium against baricitinib in RA patients; a rat adjuvant model showed Cr³⁺ suppresses joint inflammation via FOXP3 upregulation and Cathepsin G inhibition (PMID 35829940); and observational studies from 1975–1986 found that RA patients have significantly lower serum chromium levels than healthy controls (PMIDs 1153978, 3776595), supporting a deficiency hypothesis. For osteoarthritis, no comparable signal exists.
Clinical Trial Evidence
⚠️ All trials retrieved for Chromium + Osteoarthritis involve chromium as a component of cobalt-chromium orthopedic implants, not as a therapeutic agent. These trials monitor metal ion safety and device performance. They are listed for transparency but do not constitute evidence for chromium supplementation in OA treatment.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01493141 | N/A | Completed | 46 | Monitored systemic Cr and Co ion levels from metal-on-metal hip resurfacing in OA patients; chromium is the exposure source under investigation, not a treatment. |
| NCT00293774 | N/A | Completed | 1,632 | Large provincial RCT comparing metal-on-metal hip resurfacing vs. conventional total hip replacement for degenerative hip disease; long-term safety and effectiveness data collected over 17 years. |
| NCT00962351 | N/A | Completed | 120 | Multi-center RCT comparing blood and urine Cr/Co/Ti ion levels across metal-on-metal vs. metal-on-polyethylene hip bearing surfaces. |
| NCT01336595 | Phase 4 | Completed | 331 | Double-blind RCT comparing oxidized zirconium vs. cobalt-chromium femoral components in total knee arthroplasty; CoCr serves as the standard comparator. |
| NCT00862511 | N/A | Completed | 120 | Randomized comparison of serum Cr, Co, Mo, and Ni levels between coated and uncoated total knee prostheses to assess passivation surface effectiveness. |
| NCT02154516 | N/A | Completed | 26 | Pilot study of hard-on-hard total hip replacement (R3 ODH-ODH) safety and efficacy vs. metal-on-polyethylene control in non-inflammatory arthritis; 11-year follow-up. |
| NCT03382652 | N/A | Completed | 83 | Multi-center prospective post-market surveillance of the Continuum Metal Bearing System in primary total hip arthroplasty; survival and outcomes data. |
| NCT04585022 | N/A | Terminated | 75 | RCT comparing whole-blood Cr and Co concentrations in metal-on-metal THA vs. hip resurfacing at 5-year follow-up; terminated. |
| NCT06578897 | N/A | Completed | 118 | Retrospective outcomes study of revision TKA using Medacta GMK Revision with 3D metal tibial and femoral cones; post-market clinical follow-up. |
| NCT00759993 | Phase 2 | Terminated | 60 | The only trial using chromium as a therapeutic agent: chromium picolinate supplementation to prevent serotonergic medication–induced weight gain in psychiatric inpatients. Not related to OA; terminated early. |
Literature Evidence
Currently no related literature available for therapeutic chromium in osteoarthritis.
Safety Considerations
Please refer to the package insert for safety information.
Critical note on valence state: Chromium’s safety profile differs fundamentally by oxidation state. Trivalent chromium (Cr³⁺) — the nutritionally active form used in supplements (picolinate, nicotinate, chloride) — has a generally favorable safety profile at dietary doses. Hexavalent chromium (Cr⁶⁺) is a Group 1 carcinogen (IARC classification) and acutely toxic. Any therapeutic development program must explicitly specify, characterize, and verify the Cr³⁺ formulation; inadvertent Cr⁶⁺ contamination would be a disqualifying safety concern.
Conclusion and Next Steps
Decision: Hold (for Osteoarthritis)
Rationale: The TxGNN rank 1 prediction for osteoarthritis (98.68%) is most likely a knowledge graph artifact driven by the structural association between OA, orthopedic joint replacement, and cobalt-chromium implant alloys — not a genuine therapeutic signal. No clinical trials test chromium supplementation as a treatment for OA, no supporting literature was identified, and no plausible direct mechanistic pathway links chromium to OA pathophysiology beyond the general anti-inflammatory properties shared with other joint diseases. Investment in pursuing chromium for OA is not justified at this stage.
Recommended pivot: Rheumatoid Arthritis (rank 3) should be evaluated as the priority indication, with a separate “Proceed with Guardrails” review:
- A completed Phase 2/3 RCT (NCT05545020, n=60) compared trivalent chromium directly against baricitinib in RA patients, with published results (PMID 39030450, Inflammopharmacology, 2024)
- Pre-clinical evidence shows Cr³⁺ suppresses adjuvant-induced RA in rats via FOXP3 upregulation and Cathepsin G inhibition (PMID 35829940)
- RA patients have documented lower serum chromium vs. healthy controls, supporting a deficiency-correction mechanism (PMIDs 1153978, 3776595)
- Mechanistic plausibility: insulin sensitization reduces systemic inflammation; NF-κB suppression reduces TNF-α and IL-6
To advance the RA pathway, the following is needed:
- Critical appraisal of NCT05545020 full results: enrollment criteria, blinding adequacy, primary endpoints, effect sizes, and adverse event profile
- Independent multi-center replication — the published RCT appears to originate from a single research group; external validation is essential before drawing firm conclusions
- Formulation and dose optimization: which Cr³⁺ salt (picolinate vs. chloride vs. nicotinate)? Optimal dose and duration for anti-inflammatory effect?
- Long-term safety data for supranutritional Cr³⁺ dosing, particularly renal excretion and accumulation
- Health Canada regulatory pathway consultation: classification of chromium as an investigational therapeutic vs. natural health product, and implications for IND filing
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.